Thirty-three patients with obesity and obstructive sleep apnea were assessed for a Roux-en-Y gastric bypass at a hospital in Bogotá. Thirty were operated on. Eighteen came back for the second sleep study.
The 18 who returned had lost, on average, a third of their body mass: 104.4 kg to 68.5 kg, a mean BMI from 38.8 to 25.8 — the middle of the normal range. Their apnea-hypopnea index fell from 23.7 to 8.7 events an hour, a mean drop of 14.96 (95% CI 11.22 to 18.69). And 15 of the 18 still scored at or above the threshold that defines the disease, a residual rate of 83.3%.
The comorbidity that does not leave with the weight
The study is a single-centre prospective before-and-after series, published in Sleep and Breathing on 29 October — observational, with no control group and no randomised allocation. Every participant had pre- and postoperative polysomnography, anthropometry and a nasofibrolaryngoscopy, which puts it ahead of the usual claims built on symptom questionnaires. Six months is also early; the same cohort has not yet been followed to the point where weight regain usually begins.
Its authors are careful about what they found. They report favourable movement in upper-airway findings, daytime sleepiness and quality-of-life measures, and then write that “complete remission was uncommon” and that postoperative sleep reassessment “remains important.”
Whether an index of 8.7 off CPAP needs treating is a question this design cannot answer: the figure sits in the mild band, and the study measured no cardiovascular or crash outcomes. What it can say is narrower: the number stopped being normal when the weight did.
What the pooled literature says, and how it says it
The largest synthesis, a systematic review and meta-analysis of 32 studies and 2,310 patients led from the University of Jordan, found surgery moved the index by a weighted mean of 19.3 events an hour (95% CI 14.6 to 23.9), BMI by 11.9 points, and put OSA remission at 65% (95% CI 54 to 76). Those are 2023 figures, pooled from cohort and case-control designs only and restricted to studies with a postoperative sleep study — an inclusion criterion that counts only patients who agreed to be retested.
Set the pooled remission rate beside the Bogotá residual rate and they are not as far apart as they look: one says about a third do not remit, the other that a small selected group at six months mostly did not. The review’s conclusion is the interesting part — a rate well below 100%, its authors argue, suggests the etiology is not adiposity alone but includes anatomy a sleeve or a bypass never touches.
The curve that flattens
A second meta-analysis, this one in Sleep Medicine in 2024, reframes the question as a dose-response. Pooling 27 studies and 32 treatment arms — 15 surgical, 15 lifestyle, 2 pharmacological, all in people with an index of at least 15 — it found that a 20% reduction in BMI tracked with roughly a 57% reduction in the apnea-hypopnea index, and that weight loss beyond 20% bought progressively less. The quadratic term was statistically significant; the prediction intervals were wide enough that the authors declined to call the relationship precise.
That shape explains the Bogotá result without excusing it: a 33% BMI reduction against a 63% index reduction lands close to what the curve predicts, but the curve approaches a floor, not zero. Three of the six authors are Eli Lilly employees and shareholders, and the first author discloses income from the company for medical education.
What the drug trials measured instead
The comparison clinicians wonder about comes from SURMOUNT-OSA, two phase 3 randomised trials in the New England Journal of Medicine in 2024. In adults with moderate-to-severe apnea — mean index 51.5 and 49.5, BMI about 39 — 52 weeks of tirzepatide lowered the index by 25.3 and 29.3 events an hour against 5.3 and 5.5 on placebo. Lilly funded both.
The two bodies of evidence are not interchangeable. The drug trials enrolled patients roughly twice as sick, kept them to a protocol-mandated sleep study at a fixed endpoint, and had a placebo arm that also improved — by about five events an hour. The surgical series has no such arm; nobody can say how much of its 14.96-point fall would have happened anyway.
The denominator nobody counts
Twelve of the thirty operated patients never had the second study — less a criticism of one centre than a description of the literature: the patients most likely to skip an overnight test are the ones who feel cured, and they are invisible in every remission rate published.
What would settle it is unglamorous — repeat polysomnography at pre-specified intervals in a defined operated population, with outcomes adjudicated the way the LABS study, funded by NIDDK, handled its scheduled prospective follow-up. Until a cohort like that reports, the honest advice to a patient is not that the apnea will disappear. It is that the BMI on the calculator is not the same measurement as the one taken overnight, and that the second study is the one that tells you where you stand.
This archive is independent of NIH and NIDDK and reports published research only; nothing here is medical advice.
Sources
- Bonilla LFS, et al. Changes in obstructive sleep apnea severity, upper-airway findings, and health-related quality of life after Roux-en-Y gastric bypass: a prospective before-and-after study. Sleep and Breathing, 29 October 2026.
- Al Oweidat K, et al. Bariatric surgery and obstructive sleep apnea: a systematic review and meta-analysis. Sleep and Breathing, 2023.
- Malhotra A, et al. Weight reduction and the impact on apnea-hypopnea index: a systematic meta-analysis. Sleep Medicine, 2024.
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024.